Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PLA-695 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| PLA-695 | DRUG | - |
| Naproxen | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years * RA disease onset after 16 years of age and has had the disease for at least 6 months * Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once w...
PLA-695 is an investigational small molecule being studied for use in healthy volunteers and in adults with rheumatoid arthritis. It is in Phase 1 clinical development for immunology-related conditions. PLA-695 is not approved and remains under investigation.
PLA-695 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company is conducting early-stage clinical research on this investigational small molecule.
PLA-695 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Its clinical program includes completed Phase 1 studies in healthy volunteers and in adults with rheumatoid arthritis.
PLA-695 has been studied in two completed Phase 1 trials. NCT00366262 evaluated gastrointestinal safety compared to placebo and naproxen in healthy volunteers in the United States. NCT00440492 evaluated a pharmacokinetic interaction with methotrexate in adults with rheumatoid arthritis in the United States and Canada.
No alternative names for PLA-695 have been reported. The drug is identified solely by the code name PLA-695 in its clinical trial records and development program.